한빛사 논문
Ji Yun Noha,b, Hee Jin Cheonga,b, Woo Joo Kima,b, Ju-Yeon Choic, Hye Won Leec, Sung Soon Kimc, Byoungguk Kimc,*, Joon Young Songa,b,*
aDivision of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, South Korea
bVaccine Innovation Center-KU Medicine (VIC-K), Seoul, South Korea
cDivision of Vaccine Clinical Research Center for Vaccine Research, National Institute of Infectious Diseases, Cheongju, South Korea
*Corresponding author.
Abstract
Dear editors,
In response to the continued emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and the time-dependent decline in neutralizing antibodies (nAbs) after coronavirus disease 2019 (COVID-19) vaccination, various strategies for repeated vaccination have been adopted (1, 2, 3). There may be significant differences in vaccine immune response depending on whether the person is previously infected with SARS-CoV-2, the time elapsed after recovery from infection, and the interval between vaccinations. Those are very important to establish an optimal vaccination strategy in a situation where the COVID-19 transitions to endemic spread and repeated vaccinations must be considered. In the previous study by Mak et al., a second COVID-19 vaccination in prior-infected individuals did not further increase anti-SARS-CoV-2 immunoglobulin G responses in comparison to single-dose vaccination (4). Thus, we evaluated anti-SARS-CoV-2 neutralizing antibody responses in wild-type (WT) SARS-CoV-2-infected individuals who received the primary series and booster dose of BNT162b2.
논문정보
관련 링크
연구자 키워드
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기